Fulfilling the Promise of Personalized Medicine in gMG: Treatment in the Era of COVID-19

CME: 0.25

Target Audience

The intended audience for this activity are neurology, neuromuscular, neuroimmunology, and neuro-ophthalmology specialists, along with advanced practice neurology practitioners, such as neurology NPs, neurology PAs, and clinical pharmacists.

Program Overview

The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.

This case discussion will illustrate the most appropriate and evidence-based treatment selections for a man presenting with ptosis OD and a patient with AchR+ MG with COVID-19. These cases will review the burden of disease and unmet needs faced by patients with gMG, while enhancing clinicians’ ability to identify patient preferences and goals and encourage shared decision-making.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the burden of gMG disease and its treatment with traditional options
  • Describe how accounting for patient characteristics (autoantibody status, MG presentation), preferences, desire to maintain autonomy, quality of life, and treatment goals can impact treatment selection

Post a comment to this article